Group 1 - The core announcement is that Hutchison China MediTech Limited (和黄医药) has successfully negotiated with the National Healthcare Security Administration of China to include its drugs, Elunate (爱优特), Orpathys (沃瑞沙), and Sulanda (苏泰达), in the new version of the National Medical Insurance Drug List effective from January 1, 2026 [1] - Tazverik (达唯珂) has been included in the inaugural National Commercial Health Insurance Innovative Drug List, indicating a significant step for the company's product portfolio in the commercial insurance sector [1]

Core Insights - Hutchison China MediTech Limited (HCM) announced the renewal of its medical insurance agreements with the National Healthcare Security Administration (NHSA) for several of its drugs, effective from January 1, 2026 [1][2] - The inclusion of ELUNATE® (fruquintinib), ORPATHYS® (savolitinib), and SULANDA® (surufatinib) in the updated National Medical Insurance Drug List signifies continued support for innovative cancer treatments in China [1][2] - TAZVERIK® (tazemetostat) has been added to the inaugural Commercial Health Insurance Innovative Drug List, enhancing access to advanced therapies for patients with specific conditions [1][2] Drug-Specific Summaries - ELUNATE® is approved for use in combination with the anti-PD-1 therapy, sintilimab, for treating advanced endometrial cancer patients who have failed prior systemic anti-tumor therapy and are not suitable for curative surgery or radiotherapy [1] - ELUNATE® is also renewed for treating metastatic colorectal cancer patients who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, as well as those who have received or are unsuitable for VEGF and EGFR-targeted therapies [1] - ORPATHYS® is included for treating adults with locally advanced or metastatic non-small cell lung cancer harboring MET exon 14 alterations [1][2] - SULANDA® is renewed for treating unresectable locally advanced or metastatic, progressive, non-functional, well-differentiated (G1, G2) neuroendocrine tumors of pancreatic and non-pancreatic origin [2] - TAZVERIK® is included in the Commercial Health Insurance Innovative Drug List for adult patients with EZH2 mutation-positive relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [2] Policy and Market Implications - The NHSA's announcement of the 2025 adjustment plan for the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List highlights a focus on high-innovation, clinically valuable drugs that exceed the basic insurance coverage [2] - The establishment of the Commercial Health Insurance Innovative Drug List aims to enhance patient access to breakthrough therapies and supports the sustainable development of China's innovative pharmaceutical industry [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表⽰，概不 對因本公告全部或任何部分內容⽽產⽣或因倚賴該等內容⽽引致的任何損失承擔任何責任。 ⾃願性公告 和⿈醫藥宣佈商業化產品的國家醫保藥品⽬錄覆蓋範圍進⼀步擴⼤ 並獲納⼊⾸版國家商保創新藥⽬錄 和⿈醫藥（中國）有限公司（簡稱「和⿈醫藥」或「HUTCHMED」）今⽇宣佈，經過與中國國家醫療保障局（「國 家醫保局」）的醫保續約，愛優特®（ELUNATE®）、沃瑞沙®（ORPATHYS®）和蘇泰達®（SULANDA®）將繼續獲納 ⼊⾃2026年1⽉1⽇起⽣效的新版《國家基本醫療保險、⼯傷保險和⽣育保險藥品⽬錄》（「國家醫保藥品⽬錄」）。 此外，達唯珂®（TAZVERIK®）獲納⼊⾸版國家商業健康保險創新藥品⽬錄（簡稱「商保創新藥⽬錄」)。 愛優特®（呋喹替尼/ fruquintinib）獲納⼊聯合達伯舒®（信迪利單抗注射液）⽤於治療既往系統性抗腫瘤治療後 失敗且不適合進⾏根治性⼿術治療或根治性放療的晚期錯配修復完整（pMMR）⼦宮內膜癌患者。愛優特®還獲續 約⽤於治療既往接受過氟尿嘧啶類、奧沙利鉑和 ...

Core Viewpoint - HUTCHMED has successfully renewed contracts with the China National Healthcare Security Administration (NHSA), ensuring the inclusion of its drugs ELUNATE, ORPATHYS, and SULANDA in the updated National Reimbursement Drug List (NRDL) effective January 1, 2026, and the addition of TAZVERIK to the National Commercial Health Insurance Innovative Drug List [1][4]. Group 1: Drug Inclusion and Details - ELUNATE (fruquintinib) is included for treating advanced endometrial cancer with pMMR tumors and metastatic colorectal cancer patients who have undergone prior chemotherapy [2]. - ORPATHYS (savolitinib) is included for adult patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration [3]. - SULANDA (surufatinib) is renewed for treating unresectable, locally advanced or metastatic, progressive non-functional well-differentiated neuroendocrine tumors [3]. - TAZVERIK (tazemetostat) is included in the Commercial Insurance Drug List for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation [4]. Group 2: Reimbursement Framework - The new Commercial Insurance Drug List, established by the NHSA, focuses on innovative medicines with significant clinical value, enabling reimbursement through various commercial health insurance products [4]. - As of the end of 2024, approximately 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the population, highlighting the government's commitment to improving drug affordability [5]. Group 3: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [10]. - The company has successfully brought its first three medicines to market in China, with one also approved globally [10].

Group 1: Company Highlights - The new generation industrial-grade interactive humanoid robot "Spirit G2" is undergoing final factory testing, with a procurement contract exceeding 100 million yuan for delivery to Yujin Electronics' automotive parts factory [1] - ZhiYuan Robotics, founded in Pudong two years ago, has emerged as a leader in humanoid robot commercialization, reflecting the development of the Pudong New Area over the past five years [1][3] - As of September 2025, ZhiYuan Robotics has achieved significant growth in delivery volume, with thousands of units delivered across various sectors including research, education, interactive services, and industrial operations [4] Group 2: Industry Growth - The Pudong New Area has seen a remarkable economic performance, with a projected GDP of 1.78 trillion yuan in 2024, a nearly 35% increase from 2020, and a per capita GDP of $43,000, surpassing Italy [1][4] - The high-end industrial clusters in Pudong are thriving, with the integrated circuit, biomedicine, and artificial intelligence sectors reaching a combined scale of 832.3 billion yuan in 2024, growing at an average annual rate of 11.7% over the past three years [8] - The biopharmaceutical sector is also flourishing, with the innovative anti-tumor drug Fuzhuotini, developed by Huaneng Pharmaceutical, successfully entering over 30 countries and expected to reach a billion-dollar market [4][5] Group 3: Policy and Ecosystem Support - The supportive policies and innovation ecosystem in Pudong, including the "Qingchuang 15 Articles" talent policy, have fostered a conducive environment for startups and innovation [4][15] - The establishment of the Pudong New Area's "Going Global" service center has facilitated over 270 global service points, providing comprehensive support for enterprises looking to expand internationally [13] - The continuous improvement of the business environment in Pudong has led to a more than 40% increase in the number of market entities over five years, with over 200 new companies established daily [15][17]

截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | 本月底法定/註冊股本總額： USD 150,000,000 股份發行人及根據《上市規則》 ...

Core Viewpoint - Hutchison China MediTech Limited (HCM) announced the latest updates on several research studies of its self-developed compounds, which will be presented at major upcoming oncology conferences in 2025 [1] Group 1: Upcoming Presentations - Results from the first human clinical trial of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors will be presented at the ESMO Asia Congress in Singapore from December 5 to 7, 2025 [1] - The results of the FRUSICA-2 registration study's Phase II portion, which examines fruquintinib in combination with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma, will also be shared at the same ESMO Asia Congress [1] - Additionally, results from a Phase II/III study of surufatinib combined with camrelizumab and chemotherapy for first-line treatment of metastatic pancreatic cancer will be presented at the conference [1]

Core Viewpoint - Hutchison China MediTech Limited (HCM) announced the latest and updated data from several studies of its self-developed compounds, which will be presented at the European Society for Medical Oncology (ESMO) Asia Congress in Singapore and the American Society of Hematology (ASH) Annual Meeting in Orlando in December 2025 [1] Group 1: Clinical Trials and Presentations - The first human clinical trial results of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors will be presented at the 2025 ESMO Asia Congress [1] - Results from the FRUSICA-2 registration study's Phase II portion, which examines fruquintinib in combination with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma, will also be disclosed at the 2025 ESMO Asia Congress [1] - The Phase II portion results of a study combining surufatinib with camrelizumab and chemotherapy for first-line treatment of metastatic pancreatic cancer will be presented at the same congress [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 和黃醫藥將於2025年歐洲腫瘤內科學會 (ESMO) 亞洲年會和 2025年美國血液學會 (ASH) 年會公佈臨床數據 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或 「HUTCHMED」）今日宣佈和黃醫藥自主研發的化合物的數項研 究的最新及更新後的數據將於2025年12月5日至7日在新加坡召開的歐洲腫瘤內科學會（ESMO）亞洲年會，以及 2025年12月6日至9日在美國奧蘭多召開的美國血液學會（ASH）年會上公佈。 | 摘要標題 | 報告人/ 主要作者 報告詳情 | | | --- | --- | --- | | 奧希替尼聯合賽沃替尼用於治療EGFR突變伴MET過表達和/或奧希替尼治療後進展 | Se-Hoon Lee | 982P | | 的晚期非小細胞肺癌: S ...

Core Insights - HUTCHMED will present new and updated data from several studies at the upcoming ESMO Asia Congress 2025 and ASH Annual Meeting, showcasing its commitment to advancing cancer therapies [1][2][3] Group 1: Upcoming Presentations - A first-in-human study of HMPL-A83, an anti-CD47 monoclonal antibody, will be presented, focusing on advanced solid tumors [2] - The phase II results of the FRUSICA-2 study, evaluating the combination of fruquintinib and sintilimab for renal cell carcinoma, will also be shared [2] - Surufatinib's phase II results in combination with camrelizumab and chemotherapy for metastatic pancreatic cancer will be reported [2] Group 2: Specific Study Details - HMPL-A83 presentation details include a mini oral session on December 7, 2025, led by Ye Guo [2] - Fruquintinib's results will be presented by Shanshan Wang on December 5, 2025, in a proffered paper session [2] - Surufatinib's study will be displayed as a poster by Shukui Qin [2] Group 3: Additional Studies - Several investigator-initiated studies will also be presented, including combinations of fruquintinib with other treatments for metastatic colorectal cancer [3] - The final analysis of the ESLIM-01 study on sovleplenib for chronic primary immune thrombocytopenia will be presented at the ASH Annual Meeting [3] Group 4: Product Information - Fruquintinib is a selective oral inhibitor of VEGFRs, co-developed by HUTCHMED and Eli Lilly, marketed as ELUNATE in China [4] - HMPL-A83 is a humanized anti-CD47 monoclonal antibody that disrupts cancer cells' immune evasion [5] - Savolitinib is a selective MET tyrosine kinase inhibitor developed by AstraZeneca and HUTCHMED, marketed as ORPATHYS [6] - Surufatinib is an oral angio-immuno kinase inhibitor marketed as SULANDA in China [7] - Sovleplenib is a selective small molecule inhibitor targeting Syk, with potential applications in B-cell lymphomas [8]